Boehringer brings ear­ly da­ta for GLP-1 re­cep­tor show­ing al­most 15% weight loss af­ter 46 weeks

Boehringer In­gel­heim and Zealand Phar­ma re­leased Phase II da­ta on their weight loss can­di­date, a glucagon and GLP-1 re­cep­tor ag­o­nist called BI 456906, play­ing catch-up with lead­ers like No­vo Nordisk and Eli Lil­ly as the obe­si­ty mar­ket bal­loons.

The da­ta met its pri­ma­ry end­point in the dose-find­ing tri­al: up to 14.9% weight loss af­ter 46 weeks us­ing the planned main­te­nance dose. This study en­rolled pa­tients who are liv­ing with obe­si­ty or are over­weight with­out type 2 di­a­betes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER